CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Indivior PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Indivior PLC
234 Bath Road
Phone: 804-3791090p:804-3791090 SLOUGH, SL1 4EE  United Kingdom Ticker: INDVINDV
Business Summary
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board GrahamHetherington 59 1/1/2023 11/1/2019
Chief Executive Officer, Executive Director MarkCrossley 6/29/2020 2/3/2017
Chief Financial Officer, Executive Director RyanPreblick 11/19/2020 6/29/2020
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Indivior Finance S.ar.l. Luxembourg
RBP Global Holdings, Ltd. 103-105 Bath Road Berkshire United Kingdom
Indivior plc United Kingdom
Opiant Pharmaceuticals Inc 233 Wilshire Blvd, Suite 400 SANTA MONICA CA United States

Business Names
Business Name
A12FHW
Bio-Found Limited
Indivior (Beijing) Pharmaceuticals Information Consulting Co. Ltd
73 additional Business Names available in full report.

General Information
Number of Employees: 1,051 (As of 12/31/2023)
Outstanding Shares: 135,679,697 (As of 4/12/2024)
Shareholders: 10,016
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 16, 2024